Bliss GVS Pharma Reports ₹2,105.25 Lakh Profit in Q3 FY25, Revenue Up 11.3% YoY

Mumbai, January 28, 2025 – Bliss GVS Pharma Limited (NSE: BLISSGVS, BSE: 506197) has announced its Q3 FY25 financial results, reporting a net profit of ₹2,105.25 lakh, while revenue from operations increased 11.3% YoY to ₹17,959.37 lakh. The company also reviewed its potential issuance of sweat equity shares as part of its long-term incentive strategy.

Key Financial Highlights – Q3 FY25 (Standalone & Consolidated)​

For the nine months ended December 31, 2024 (9M FY25):

• Revenue: ₹51,120.22 lakh (+15.7% YoY).
• Net Profit: ₹5,751.66 lakh (+8.7% YoY).

Segment-Wise Performance & Business Highlights​

1. Domestic & International Market Growth​

• Domestic sales contributed 48.5% of total revenue, with a 10% YoY growth.
• Export sales grew 12.5% YoY, particularly in Africa and Southeast Asia.

2. Cost & Margin Trends​

• The cost of raw materials increased 9.4% YoY, impacting gross margins.
• R&D expenses are up 15.2% YoY as the company invests in new drug formulations.

Key Corporate Developments​

1. Sweat Equity Shares Proposal​

• The Board reviewed a potential issuance of sweat equity shares as part of its long-term employee incentive strategy.
• The proposal is pending further validation and policy review before final approval.

2. Regulatory & Compliance Filings​

• Bliss GVS Pharma filed its financial results as per SEBI (LODR) Regulations, 2015.
• The financials have been reviewed by Kalyaniwalla & Mistry LLP, and no material misstatements have been reported.

Management Commentary​

Dr. Naresh Kumar, Managing Director, Bliss GVS Pharma, stated:
"Our strong revenue growth reflects the success of our international expansion strategy and continued focus on product innovation. We remain committed to delivering shareholder value while exploring strategic growth opportunities."

Strategic Outlook & Market Expansion​

• Increased investment in R&D for specialty generics.
• Strengthening presence in Africa & Southeast Asia through new product launches.
• Further evaluation of incentive-based sweat equity issuance to retain key talent.

With steady revenue growth, strategic expansion, and continued R&D investment, Bliss GVS Pharma is well-positioned for long-term profitability in the pharmaceutical sector.